Spots Global Cancer Trial Database for Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Official Title: Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide

Study ID: NCT00809276

Conditions

Lymphoma

Multiple Myeloma

Leukemia

Myelodysplastic Syndrome

Interventions

Busulfan, Fludarabine, Cytoxan

Study Description

Brief Summary: The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

Detailed Description: A person who has cancer of the blood or lymph glands can be treated by bone marrow transplantation (BMT). BMT has developed over several decades of research on both animal and human subjects as an effective treatment of various malignant and nonmalignant hematologic diseases. Many hematologic malignancies can be successfully treated with a combination of high-dose chemotherapy or chemo-radiotherapy and transplantation of allogeneic bone marrow or peripheral blood stem cells (alloBMT) However, a possible side effect of BMT is graft versus host disease (GVHD). GVHD occurs when cells of the donor's immune system, which are present in the bone marrow, attack the BMT recipient's normal tissue. Prevention of GVHD is important for the success of the bone marrow transplant. This research is being done to find the most effective and least toxic way to prevent GVHD after BMT